Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | AOC2 | O75106 | 2/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14476867 | 0.95 | HDAC1 (0.58) | HDAC1HDAC8ALDH1A1MAPK8CNR2 | |
| SCHEMBL11796135 | 0.85 | AOC2 (0.66) | HDAC8AOC2AOC3 | |
| SCHEMBL8566065 | 0.83 | HDAC1 (0.61) | HDAC1HDAC8ALDH1A1MAPK8CNR2 | |
| SCHEMBL29995593 | 0.82 | HDAC1 (0.56) | HDAC1HDAC8ALDH1A1MAPK8CNR2 | |
| SCHEMBL30545010 | 0.81 | ESRRB (0.58) | ALDH1A1NLRP3AOC2EPHX2AOC3 | |
| SCHEMBL8640586 | 0.81 | TACR1 (0.55) | HDAC1HDAC8ALDH1A1BACE1BACE2 | |
| SCHEMBL754150 | 0.80 | GAA (0.63) | ALDH1A1MAPK8AOC2AOC3KDM4E | |
| SCHEMBL1567951 | 0.80 | CA2 (0.57) | HDAC1HDAC8MAPK8PIK3CATAAR1 | |
| SCHEMBL4305804 | 0.79 | PIK3CA (0.56) | HDAC1HDAC8MAPK8CNR2NLRP3 | |
| SCHEMBL6867356 | 0.79 | MEN1 (0.68) | HDAC1HDAC8ALDH1A1MAPK8AOC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409611-A | Oxadiazole hydrazide compound and preparation method and application thereof | 贵州大学 | 2022-04-29 | — | — | CN | disclosed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2173743-A2 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012242-A2 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| CN-1191255-C | Benzodiazepine derivatives as GABA A receptor modulators | HOFFMANN LA ROCHE (CH) | 2005-03-02 | — | — | CN | disclosed |
| EP-1337535-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-06-09 | — | — | EP | disclosed |
| US-6743789-B2 | SUBSTITUTED IMIDAZO (1,5-A) (1,2,4) TRIAZOLO (4,3-D) (1,4) BENZODIAZEPINE DERIVATIVES ARE USEFUL FOR TREATING ALZHEIMER'S DISEASE; REACTING A BEZODIAZEPINE DERIVATIVE WITH A HYDRAZIDE DERIVATIVE TO FORM END PRODUCT | HOFFMANN-LA ROCHE INC. | 2004-06-01 | — | — | US | disclosed |
| CN-1474820-A | Benzodiazepine derivatives as GABA A receptor modulators | - | 2004-02-11 | — | — | CN | disclosed |
| EP-1337535-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002040487-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
| EP-0567982-B1 | Azole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5466820-A | Fungicides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| US-5371101-A | Fungicides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0567982-A1 | Azole compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | HDAC1 2095/4885HDAC8 1486/4885ALDH1A1 278/4885 |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | HDAC1 621/4885HDAC8 1528/4885ALDH1A1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.